tiprankstipranks
Advertisement
Advertisement
Is CTNM a Buy, Before Earnings?
PremiumPre-EarningsIs CTNM a Buy, Before Earnings?
2M ago
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
Premium
Company Announcements
Contineum Therapeutics Adopts 2026 Employment Inducement Equity Plan
3M ago
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
Premium
The Fly
Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
4M ago
Contineum price target lowered to $22 from $25 at RBC Capital
PremiumThe FlyContineum price target lowered to $22 from $25 at RBC Capital
5M ago
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
Premium
Ratings
Contineum Therapeutics: Undervalued Potential in IPF with PIPE-791 Amidst PIPE-307 Setback
5M ago
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
Premium
Ratings
Positive Outlook on Contineum Therapeutics Despite Setbacks, Driven by PIPE-791’s Potential in IPF
5M ago
Contineum Phase 2 VISTA trial did not meet primary, secondary endpoints
PremiumThe FlyContineum Phase 2 VISTA trial did not meet primary, secondary endpoints
5M ago
Contineum Therapeutics Inc trading halted, news pending
Premium
The Fly
Contineum Therapeutics Inc trading halted, news pending
5M ago
Buy Rating for Contineum Therapeutics: Promising Advancements in Clinical Pipeline and Strategic Opportunities
Premium
Ratings
Buy Rating for Contineum Therapeutics: Promising Advancements in Clinical Pipeline and Strategic Opportunities
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100